Loading…
← CockpitCompetitor Analysis › NANO.PA Nanobiotix SAOpen in the cockpit ↗

Nanobiotix SANANO.PACompetitor analysis, valuation and peers

France · EUR·Health Care›Pharmaceuticals: Major

French clinical-stage biotech developing a nanoparticle injected into tumors to enhance the effect of radiotherapy.

≈ A radiotherapy-enhancement biotech, unlike any single US analogueMomentum laggard 10
Mkt cap
$1.35B
US dollars, full cap
Free float
86%
of shares outstanding
$/day
$6.12M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 8.2%
Hurdle
n/a
no reverse DCF
Next earnings
160 days
27 Apr 2027
Close · EUR€24.08
1D-2.5%
1W-17.2%
1M+13.6%
3M-36.7%
6M-31.9%
YTD+23.5%
1Y+32.3%
ATR %7.8%
52w lowhigh49.5% off high

What Nanobiotix does

French clinical-stage biotech developing a nanoparticle injected into tumors to enhance the effect of radiotherapy.

Has no commercial revenue to speak of: income comes from licence payments, notably the 2019 deal with Janssen, Johnson & Johnson's pharmaceutical arm, which gave it a partner outside the US. Hensify has a European CE mark for soft-tissue sarcoma but is mostly a development-stage product.

In one line: A radiotherapy-enhancement biotech, unlike any single US analogue.

Products and services

  • NBTXR3 (Hensify) nanoparticle radioenhancer

Customers

  • Radiation oncology centers
  • Pharma partners (licensing deals)

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • Oncology radioenhancer therapeutics

What could go right

  • Pivotal trial readouts/approvals
  • Pharma partnership/licensing deals

What could go wrong

  • Clinical trial failure risk
  • Ongoing cash burn/dilution

Moat: narrow (IP / patents, regulatory licence). Patented nanoparticle technology with regulatory approval in some markets, but unproven at commercial scale.

Headquarters: Paris, France · Founded: 2003 · Employees: 97

Named competitors

Nanobiotix at a glance

Size Nanobiotix (NANO.PA) is a France Health Care company (Pharmaceuticals: Major) with a market value of $1.35B, the 121st largest of 206 France companies the cockpit tracks. Shares closed at €24.08 on 18 Nov 2026.

Performance Over six months the shares fell 31.9%, against -14.7% for the median peer and -2.1% for the France market (cap-weighted) — 4th lowest of 20 in its peer set.

Growth Revenue fell 76.9% over the last twelve months (peer median +12.4%); the operating margin is -392.0% (peer median 10.9%).

Valuation It trades at 146.3× enterprise value to sales against a peer median of 4.0× (3rd most expensive of 18).

Next results Next results expected around 27 Apr 2027 (exchange calendar; dates can move).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 87NANO.PA 70
Six months, rebased to 100: Nanobiotix against the median of its 20 peers (local-currency closes).

Nanobiotix financials

Reported figures in EUR; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue€8.36M€29.6M-€11.6M€30.1M€0
Revenue growth——-139%——
Gross profitn/an/an/an/a-€1.50M
EBITDA-€31.2M-€12.2M-€71.1M-€28.9M-€49.0M
Net income-€52.9M-€24.0M-€68.1M-€39.7M-€57.0M
Free cash flow-€40.2M-€35.5M-€21.4M-€19.8M-€38.1M
Capital expenditure€1.01M€546,000€848,000€337,000€93,000
Total debtn/a€95.3M€50.9M€50.6M€53.2M

Quarterly statements and history in the cockpit →

Nanobiotix competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%300181226950002099068760688293MNKDINVA002020OCULLBRX301263002332DMRAMARKSANS310210AMPH140410300204NANO.PA6-month return →1-month return →
Up and to the right = strong over both horizons. Nanobiotix is the large dot.

Fundamentals: revenue growth against valuation

-100%0%+100%0×25,000×50,000×75,000×300181226950688293002020OCUL310210300204NANO.PARevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Nanobiotix is the large dot.

Nanobiotix competitors and peer comparison

Head to head with its named competitors (NANO.PA vs SHL.DE vs BSX)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Nanobiotix NANO.PA$1.35B-32%-77%-392%146.3×n/a
Siemens Healthineers SHL.DE$53.7B+27%+1%14%2.6×9.6%
Boston Scientific BSX$63.3B-23%+9%21%3.5×5.8%

How Nanobiotix compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Nanobiotix against its 20 peers (data as of 18 Nov 2026)
MeasureNANO.PAPeer medianRank in peer set
1-month return+13.6%-2.3%3rd highest of 20
6-month return-31.9%-14.7%4th lowest of 20
Distance from 52-week high-49.5%-40.0%6th lowest of 20
Revenue growth (TTM)-76.9%+12.4%2nd lowest of 18
Operating margin-392.0%10.9%3rd lowest of 18
EV / Sales146.3×4.0×3rd most expensive of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Nanobiotix NANO.PAFrance$1.35B-32%-77%-392%146.3×n/an/a
Zhejiang Jolly Pharmaceutical 300181.SZChina$1.34B-15%+17%20%3.0×3.9%+22.8%
OliX Pharmaceuticals 226950.KSSouth Korea$1.35B-51%+27%-384%125.0×n/an/a
Zhejiang Hisoar Pharmaceutical 002099.SZChina$1.33B-2%+9%-13%4.7×n/an/a
Celltrion Pharm 068760.KSSouth Korea$1.33B-23%+16%12%3.0×10.2%+18.1%
Shanghai OPM Biosciences 688293.SSChina$1.32B+36%+133%11%9.6×25.9%+23.1%
Windward Bio WWBUnited States$1.31Bn/an/an/an/an/an/a
MannKind MNKDUnited States$1.31B+25%+32%-2%4.0×n/an/a
Innoviva INVAUnited States$1.31B-17%+12%38%2.2×-17.2%+3.9%
Zhejiang Jingxin Pharmaceutical 002020.SZChina$1.39B-19%+1%19%2.1×-9.6%+4.6%
Ocular Therapeutix OCULUnited States$1.31B-26%-10%-681%17.0×n/an/a
LB Pharmaceuticals LBRXUnited States$1.30B+43%n/an/an/an/an/a
Guangdong Taienkang Pharmaceutical 301263.SZChina$1.30B-24%+2%-2%12.8×n/an/a
Zhejiang Xianju Pharmaceutical 002332.SZChina$1.28B-1%+8%11%2.0×-0.4%-1.3%
Damora Therapeutics DMRAUnited States$1.42B-5%n/an/an/an/an/a
Nippon Shinyaku 4516.TJapan$1.42B-20%+18%18%0.8×-18.1%+7.0%
Marksans Pharma MARKSANS.NSIndia$1.43B+36%+24%20%3.8×31.0%+16.6%
Voronoi 310210.KSSouth Korea$1.43B-62%-100%-438,152%85,633.6×n/an/a
Amphastar Pharmaceuticals AMPHUnited States$1.27B+64%+3%19%2.3×2.5%+15.5%
Mezzion Pharma 140410.KSSouth Korea$1.43B-15%+13%-211%216.0×n/an/a
Staidson (Beijing) Biopharmaceuticals 300204.SZChina$1.26B-41%-24%-51%39.1×n/an/a

Questions

Who are Nanobiotix's main competitors?
Named competitors: Varian (Siemens Healthineers) (SHL.DE), Boston Scientific (BSX), Galera Therapeutics (private or unlisted). The cockpit's measured peer set (industry) also includes Zhejiang Jolly Pharmaceutical (300181.SZ), OliX Pharmaceuticals (226950.KS), Zhejiang Hisoar Pharmaceutical (002099.SZ), Celltrion Pharm (068760.KS), Shanghai OPM Biosciences (688293.SS), Windward Bio (WWB).
Is Nanobiotix expensive compared with its peers?
On ev / sales it trades at 146.3× against a peer median of 4.0×, 3rd most expensive of 18 in its peer set.
How has Nanobiotix stock performed?
Over six months to 18 Nov 2026 the shares returned -31.9% against -14.7% for the median peer; over one year +32.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.